v3.26.3
Related Party Transactions
 9 Months Ended
Sep. 30, 2026
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
The Company has various business agreements with certain third-party companies in which there is some common ownership and/or management between those entities, on the one hand, and the Company, on the other hand. The Company has no direct ownership or management in any of such related party companies. Except as disclosed below, as of and for the three and nine months ended September 30, 2026, there were no material changes to our related party agreements or relationships as defined and described in Note 22. Related Party Transactions and Note 20. Stockholders’ (Deficiency) Equity in the Company’s 2025 Annual Report on Form 10-K.
The following table summarizes the Company’s related party transactions (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
Related Party and Nature of TransactionCaption in Balance Sheet and Statement of Operations2026202520262025
Kashiv (1)
Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko and Fylnetra)Cost of goods sold$1,654 $3,353 $7,533 $11,148 
Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko and Fylnetra)Inventory and cost of goods sold$407 $3,602 $5,042 $9,218 
Generic development supply agreement - recognition of deferred incomeResearch and development$(163)$— $(163)$— 
Development and commercialization agreement - OmalizumabResearch and development$— $22,500 $— $22,500 
Generic development supply agreement - research and development materialResearch and development$— $(502)$— $(502)
Storage agreementResearch and development$— $(71)$— $(189)
Development and commercialization agreement - Pegfilgrastim Auto Injector - milestoneResearch and development$— $— $500 $3,000 
Development and commercialization agreement - CarfilzomibResearch and development$— $— $— $2,000 
Parking space leaseResearch and development$— $— $— $25 
Generic development supply agreement - development activity deferred incomeAccounts payable and
accrued expenses		$— $— $— $(99)
Other Related Parties
Members - tax receivable agreementIncrease (decrease) in tax receivable agreement liability$12,992 $(20,808)$13,098 $(5,701)
Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreementInventory and cost of goods sold$5,067 $4,634 $16,218 $15,973 
Sellers of Kashiv - change in fair value of contingent consideration (2)
Change in fair value of contingent consideration$(6,000)$— $(6,000)$— 
AzaTech Pharma LLC - supply agreementInventory and cost of goods sold$861 $185 $2,545 $2,512 
Kanan, LLC - operating leaseInventory and cost of goods sold$654 $592 $1,938 $1,776 
Sutaria Family Realty, LLC - operating leaseInventory and cost of goods sold$405 $333 $1,143 $987 
PharmaSophia, LLC - License and commercialization agreement - Risperidone - Royalty expenseCost of goods sold$314 $— $1,178 $— 
Direct Customer Solutions, LLC - warehousing/logistics/distribution servicesSelling, general and administrative$166 $— $295 $— 
Twenty NEA, LLC - operating lease (3)
Cost of goods sold$104 $— $104 $— 
Tracy Properties LLC - operating leaseSelling, general and administrative$81 $152 $248 $478 
Avtar Investments, LLC - consulting servicesResearch and development$60 $60 $180 $180 
AvPROP, LLC - operating leaseSelling, general and administrative$48 $46 $130 $150 
Avtar Investments, LLC - office rental space (3)
Selling, general and administrative$34 $— $34 $— 
Land purchase from family members of the Co-Chief Executive OfficersProperty, plant and equipment$— $— $— $11,289 
Ellodi Pharmaceuticals, L.P. - securities purchase and license and collaboration agreementsResearch and development$— $338 $— $6,046 
R&S Solutions - equipment purchaseProperty, plant and equipment$— $47 $— $207 
Alkermes PlcInventory and cost of goods sold$— $3 $— $67 
(1)Amounts relate to agreements previously between Amneal and Kashiv that were acquired in the Kashiv Acquisition and, following the closing of the transaction on August 10, 2026, became transactions among Amneal’s consolidated subsidiaries. Accordingly, the amounts presented for the three and nine months ended September 30, 2026 reflect activity only through August 10, 2026.
(2)Represents changes in the fair value of contingent consideration liabilities payable to the sellers of Kashiv pursuant to the Purchase Agreement.
(3)These agreements were acquired in the Kashiv Acquisition and are included in the Company’s related party disclosures for the three and nine months ended September 30, 2026 because the counterparties meet the definition of related parties. The amounts presented reflect activity from the acquisition date through September 30, 2026.
The following table summarizes the amounts due to or from the Company for related party transactions (in thousands):
September 30, 2026December 31, 2025
Preliminary working capital adjustment - sellers of Kashiv$1,814 $— 
AzaTech Pharma LLC62 56 
Kashiv - various agreements— 413 
Apace Packaging, LLC - packaging agreement— 1 
Related party receivables - short term $1,876 $470 
Members - tax receivable agreement$16,323 $38,832 
Apace Packaging, LLC - packaging agreement1,640 1,353 
AzaTech Pharma LLC - supply agreement505 254 
PharmaSophia, LLC - license and commercialization agreement314 — 
Avtar Investments LLC - consulting services74 40 
Direct Customer Solutions, LLC57 — 
Kashiv - various agreements— 14,980 
Tracy Properties LLC— 26 
Related party payables - short term $18,913 $55,485 
Members - tax receivable agreement$15,432 $18,656 
Land purchase from family members of the Co-Chief Executive Officers446 476 
Related party payables - long term $15,878 $19,132 
Master Logistics Services Agreement with DCS
On February 24, 2026, the Company entered into a master logistics services agreement with Direct Customer Solutions, LLC (“DCS”), a third-party logistics provider specializing in the life sciences industry. Under the agreement, DCS will provide logistics services on behalf of the Company, including transportation, warehousing, and end-to-end supply chain management for certain products. A member of Company management beneficially owns outstanding equity securities of DCS.
Pursuant to the agreement, the Company paid DCS an immaterial one-time setup fee, a per-unit distribution fee, and a minimum monthly maintenance fee. For the three and nine months ended September 30, 2026, the Company recorded selling, general and administrative expense of $0.2 million and $0.3 million, respectively, and a short term payable of $0.1 million as of September 30, 2026, related to these services.
License and Commercialization Agreement with PharmaSophia, LLC
PharmaSophia, LLC (“PharmaSophia”) is a joint venture formed by Nava Pharma, LLC (“Nava”) and Oakwood Laboratories, LLC for the purpose of developing certain products. Certain executive officers of the Company beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, outstanding equity securities of Nava. Nava beneficially owns 50% of the outstanding equity securities of PharmaSophia. In addition, these executive officers also serve on the Board of Managers of PharmaSophia.
In October 2022, PharmaSophia and Amneal entered into an exclusive license and commercialization agreement (the “PharmaSophia Agreement”) to develop, manufacture, and sell one injectable product (risperidone). PharmaSophia receives a 50% profit share for all sales of product made by Amneal under the PharmaSophia Agreement. For the three and nine months ended September 30, 2026, the Company recorded royalty expense of $0.3 million and $1.2 million, respectively, related to this agreement. Amounts payable to PharmaSophia under the agreement were $0.3 million as of September 30, 2026.
Agreement to Acquire Complex Products Research, LLC Non-Controlling Interest
On May 31, 2026, the Company acquired the remaining 2% non-controlling interests in CPR from the sellers of KSP, which are related parties, for cash consideration of $0.4 million. Refer to Note 19. Stockholders’ Equity (Deficiency) for additional information.
Acquisition of Kashiv Biosciences, LLC
Pre-Acquisition Related Party Transactions
On August 10, 2026, the Company completed the Kashiv Acquisition. Prior to closing of the transaction, Kashiv and the Company were related parties. Following the closing, agreements previously between Amneal and Kashiv became intercompany arrangements between Amneal’s consolidated subsidiaries. Accordingly, the amounts presented for the three and nine months ended September 30, 2026 reflect activity only through August 10, 2026. Amounts due to and from Kashiv prior to closing were settled as part of the transaction.
Certain executive officers and a member of the Company’s Board of Directors beneficially owned, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, equity interests in Kashiv and served on the Board of Managers of Kashiv prior to the acquisition date.
For additional information about related party transactions between the Company and Kashiv, refer to Note 22. Related Party Transactions in the Company’s 2025 Annual Report on Form 10-K.
Contingent Consideration and Purchase Price Adjustments
The sellers of Kashiv are eligible to receive contingent milestone and royalty payments pursuant to the Purchase Agreement. Certain sellers remain related parties of the Company, including certain executive officers and a member of the Company’s Board of Directors. As of September 30, 2026, the Company had a receivable of $1.8 million from the sellers for post-closing purchase price adjustments, presented as “Preliminary working capital adjustment - sellers of Kashiv” within related party receivables - short term in the table above. The Company also had a contingent consideration liability of $383.0 million, including $59.0 million classified as current liabilities and $324.0 million classified as long-term liabilities in the Company’s consolidated balance sheets.
Refer to Note 2. Acquisition and Note 16. Fair Value Measurements for additional information regarding the Kashiv Acquisition, including the purchase consideration, contingent consideration arrangements and preliminary purchase price allocation.
Acquired contracts with related parties
Certain agreements acquired as part of the Kashiv Acquisition are with counterparties that qualify as related parties of the Company. These agreements include an operating lease with Twenty NEA, LLC (“Twenty NEA”) under which Kashiv leases a research, development and manufacturing facility and a short-term lease arrangement with Avtar Investments, LLC (“Avtar”) to lease office space, both of which are located in the United States.
Certain executive officers and a member of the Amneal Group beneficially own, directly or through certain revocable or irrevocable trusts established for the benefit of their immediate families, equity interests in Twenty NEA. As described in Note 22. Related Party Transactions in the Company’s 2025 Annual Report on Form 10-K, certain executive officers of the Company beneficially own, directly and through certain revocable or irrevocable trusts for the benefit of their immediate families, equity securities in Avtar, a private investment firm.